[{"address1": "170 Harbor Way", "address2": "Suite 300", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 550 3500", "fax": "650 871 8580", "website": "https://vaxart.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.", "fullTimeEmployees": 105, "companyOfficers": [{"maxAge": 1, "name": "Mr. Steven  Lo", "age": 57, "title": "President, CEO & Director", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 879327, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sean N. Tucker Ph.D.", "age": 56, "title": "Senior VP & Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 622439, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James F. Cummings M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 679943, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeroen  Grasman M.B.A.", "title": "CFO, Principal Accounting Officer & Principal Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Raymond D. Stapleton Jr., Ph.D.", "age": 52, "title": "Chief Technology Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edward B. Berg", "age": 60, "title": "Senior VP & General Counsel", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Laurie  Hastings", "title": "Senior Vice President of Human Resources", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shaily Jaini Garg", "title": "Senior Vice President of Clinical Development & Project Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rajesh  Kapoor Ph.D.", "title": "Senior Vice President of Quality", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 6, "overallRisk": 9, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://newsroom.biotapharma.com/", "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.36, "open": 0.3476, "dayLow": 0.3437, "dayHigh": 0.3585, "regularMarketPreviousClose": 0.36, "regularMarketOpen": 0.3476, "regularMarketDayLow": 0.3437, "regularMarketDayHigh": 0.3585, "exDividendDate": 1352419200, "payoutRatio": 0.0, "beta": 0.883, "forwardPE": -1.0294118, "volume": 142180, "regularMarketVolume": 142180, "averageVolume": 539284, "averageVolume10days": 430030, "averageDailyVolume10Day": 430030, "bid": 0.355, "ask": 0.3599, "bidSize": 9901, "askSize": 3128, "marketCap": 84020920, "fiftyTwoWeekLow": 0.26, "fiftyTwoWeekHigh": 0.98, "allTimeHigh": 1181.4, "allTimeLow": 0.25, "priceToSalesTrailing12Months": 0.5669275, "fiftyDayAverage": 0.3648, "twoHundredDayAverage": 0.401, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 73229168, "profitMargins": -0.34212002, "floatShares": 237659543, "sharesOutstanding": 240059770, "sharesShort": 21173323, "sharesShortPriorMonth": 14348733, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.0928, "heldPercentInsiders": 0.008590001, "heldPercentInstitutions": 0.01001, "shortRatio": 2.61, "shortPercentOfFloat": 0.094, "impliedSharesOutstanding": 240059770, "bookValue": 0.117, "priceToBook": 2.991453, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -50703000, "trailingEps": -0.22, "forwardEps": -0.34, "lastSplitFactor": "1:11", "lastSplitDate": 1518566400, "enterpriseToRevenue": 0.494, "enterpriseToEbitda": -1.827, "52WeekChange": -0.49275362, "SandP52WeekChange": 0.17318606, "lastDividendValue": 12.188, "lastDividendDate": 1352419200, "quoteType": "EQUITY", "currentPrice": 0.35, "targetHighPrice": 4.0, "targetLowPrice": 2.0, "targetMeanPrice": 3.33333, "targetMedianPrice": 4.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 28793000, "totalCashPerShare": 0.12, "ebitda": -40081000, "totalDebt": 18958000, "quickRatio": 0.678, "currentRatio": 0.693, "totalRevenue": 148204000, "debtToEquity": 70.855, "revenuePerShare": 0.649, "returnOnAssets": -0.16252, "returnOnEquity": -1.06521, "grossProfits": -30876000, "freeCashflow": -7783250, "operatingCashflow": -30294000, "revenueGrowth": 13.679, "grossMargins": -0.20833, "ebitdaMargins": -0.27044, "operatingMargins": -0.10787, "financialCurrency": "USD", "symbol": "VXRT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "shortName": "Vaxart, Inc.", "longName": "Vaxart, Inc.", "fiftyTwoWeekLowChange": 0.09, "fiftyTwoWeekLowChangePercent": 0.3461539, "fiftyTwoWeekRange": "0.26 - 0.98", "fiftyTwoWeekHighChange": -0.63, "fiftyTwoWeekHighChangePercent": -0.64285713, "fiftyTwoWeekChangePercent": -49.275364, "dividendDate": 1518566400, "earningsTimestamp": 1763067600, "earningsTimestampStart": 1763067600, "earningsTimestampEnd": 1763067600, "earningsCallTimestampStart": 1763069400, "earningsCallTimestampEnd": 1763069400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.22, "epsForward": -0.34, "epsCurrentYear": -0.29, "marketState": "CLOSED", "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 376929000000, "regularMarketChange": -0.01000002, "regularMarketDayRange": "0.3437 - 0.3585", "fullExchangeName": "OTC Markets OTCQX", "averageDailyVolume3Month": 539284, "priceEpsCurrentYear": -1.2068965, "fiftyDayAverageChange": -0.014800012, "fiftyDayAverageChangePercent": -0.040570207, "twoHundredDayAverageChange": -0.051, "twoHundredDayAverageChangePercent": -0.12718205, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "regularMarketChangePercent": -2.7777834, "regularMarketPrice": 0.35, "corporateActions": [{"header": "Delisting", "message": "VXRT was delisted effective Dec. 1, 2025", "meta": {"eventType": "DELISTING", "dateEpochMs": 1764565200000}}], "regularMarketTime": 1766782800, "exchange": "OQX", "messageBoardId": "finmb_37819645", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "Vaxart", "trailingPegRatio": null, "__fetch_time": "2025-12-27"}]